Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Bipolar Disorder

In brief

Study Design This is the second study of a multiphase, multicenter trial that will comprehensively examine lithium in the treatment of pediatric participants with bipolar I disorder. In order to examine the treatment of bipolar disorder with lithium, this study will include four phases of treatment. The first phase, the Efficacy Phase, will include participants being randomized to either lithium or placebo for 8 weeks to determine the efficacy of lithium in the treatment of children and adolescents with bipolar I disorder. Once participants complete the Efficacy Phase, participants may be eligible to continue in the Long- Term Effectiveness Phase for a maximum of 24 weeks of lithium treatment. Subsequently, participants meeting response criteria during the Long-Term Effectiveness Phase will be eligible to continue in the Discontinuation Phase. During the Discontinuation Phase, participants will be randomized to either placebo or lithium treatment for up to 28 weeks. Finally, those participants who experience a mood relapse during the Discontinuation Phase will be enrolled in an Open Label Restabilization Phase and treated with lithium for up to 8 weeks.

Key facts

Study ID

NCT01166425

Run by

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

People needed

81

Starts

2010-06-01

Expected to finish

2013-04-01

Last updated by the study team

2013-10-09

Who can join

Age: 7 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants aged 7 years to 17 years, 11 months old at time of first dose
• Participants must meet DSM-IV diagnostic criteria, as assessed by a semi-structured assessment (KSADS-PL) and a separate clinical interview with a child/adolescent psychiatrist for manic or mixed episodes in bipolar I disorder
• Score of > 20 on the YMRS at screening and baseline
• The participant and legal guardian must understand the nature of the study and be able to comply with protocol requirements. The legal guardian must give written informed consent and the youth, written assent
• Participants with comorbid conditions [attention deficit hyperactivity disorder (ADHD), conduct disorder], except those listed in Exclusion Criterion 2, may participate
• If female: is premenarchal, or is incapable of pregnancy because of a hysterectomy, tubal ligation, or spousal/partner sterility. If sexually active and capable of pregnancy, has been using an acceptable method of contraception (hormonal contraceptives, intrauterine device, spermicide and barrier) for at least one month prior to study entry and agrees to continue to use one of these for the duration of the study. If sexually abstinent and capable of pregnancy, agrees to continued abstinence or to use of an acceptable method of birth control should sexual activity commence
• Has a negative quantitative serum ß-human chorionic gonadotrophin hormone pregnancy test at screening and a negative qualitative urine pregnancy test at baseline, if female
• Participants with a history of substance abuse may participate if they agree to continue to abstain from drugs during the trial and have a negative drug screen at screening or prior to baseline. Those with an initial positive drug screen during screening may have another screen done 1-3 weeks later while in screening, and a negative result will allow the participant to participate
• The participant is willing and clinically able to wash out of exclusion medications during the screening period. Prior to the administration of lithium, participants will have not used any of the following medications: antipsychotics, monoamine oxidase inhibitors, antidepressants within the preceding 2 weeks; stimulants within the preceding week; or fluoxetine or depot antipsychotics in the past month (no stable participants will be asked to discontinue medications)
• ECG and bloodwork including CBC, electrolytes, etc. (as per Safety assessment procedures listed in Table 6) showing no clinically significant abnormalities

You may not qualify if…

• Participant who is clinically stable on current medication regimen for bipolar disorder
• A current or lifetime diagnosis of Schizophrenia or Schizoaffective Disorder, a Pervasive Developmental Disorder (ASQ score > 15), Anorexia Nervosa, Bulimia Nervosa, or Obsessive-Compulsive Disorder
• Current DSM-IV diagnosis of Substance Dependence
• Positive drug screen at screening and on retest 1-3 weeks later
• Participants with symptoms of mania that may be attributable to a general medical condition, or secondary to use of medications (e.g., corticosteroids)
• Evidence of any serious, unstable neurological illness for which treatment under the auspices of this study would be contraindicated
• Any serious, unstable medical illness or clinically significant abnormal laboratory assessments that would adversely impact the scientific interpretability or unduly increase the risks of the protocol
• Current general medical condition including neurological disease, diabetes mellitus, thyroid dysfunction, or renal dysfunction that might be affected adversely by lithium, could influence the efficacy or safety of lithium, or would complicate interpretation of study results
• Evidence of current serious homicidal/suicidal ideation such that in the treating physician's opinion it would not be appropriately safe for the participant to participate in this study
• Evidence of current active hallucinations and delusions such that in the treating physician's opinion it would not be appropriately safe for the participant to participate in this study
• Concomitant prescription of over-the-counter medication or nutritional supplements (e.g., ibuprofen, naproxen, St John's wort) that would interact with lithium or affect the participant's physical or mental status
• Concomitant psychotherapy treatments provided outside the study initiated within 4 weeks prior to screening
• Previous adequate trial with Li+ (at least 4 weeks with Li+ serum levels between 0.8-1.2 mEq/L)
• History of allergy to lithium or lithium intolerance
• Psychiatric hospitalization within 1 month of screening for psychosis or serious homicidal/serious suicidal ideation
• Clinician's judgment that participant is not likely to be able to complete the study as an outpatient due to psychiatric reasons
• Females who are currently pregnant or lactating
• Sexually active females who, in the investigators' opinion, are not using an adequate form of birth control.
• Participants who are unable to swallow the study medication
• Participants for whom a baseline YMRS score of < 20 is anticipated
• Participants with an IQ less than 70 (determined using the Wechsler Abbreviated Scales of Intelligence {WASI} Vocabulary and Matrix Reasoning Subscales)

Where it is running

• Childrens National Medical Center — Washington D.C., District of Columbia, United States
• University of Illinois at Chicago — South Chicago Heights, Illinois, United States
• University of Kansas School of Medicine — Psychiatry and Behavioral Sciences, 1010 N Kansas St, Wichita, Kansas, United States
• University of Massachusetts Medical School — Biotech One Suite 100, 365 Plantation, Worcester, Massachusetts, United States
• The Zucker Hillside Hospital — Glen Oaks, New York, United States
• Columbia University — New York, New York, United States
• University of North Carolina - Chapel Hill — Department of Psychiatry, CB 7160, Chapel Hill, North Carolina, United States
• Cincinnati Childrens Hospital Medical Center — Cincinnati, Ohio, United States
• University of Cincinnati — Cincinnati, Ohio, United States
• University Hospitals Case Medical Center — Cleveland, Ohio, United States
• Seattle Childrens Hospital Research Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.